Generic Biologics Provide Significant Growth Opportunity, Barr Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr plans to limit its biotech projects to four until a regulatory pathway for follow-on biologics is established, CEO Downey says. The generic industry is arguing for “common sense” rules, he asserts.
You may also be interested in...
Barr’s First Biologic Product Candidate Is Adenovirus Vaccine
The company is developing the product under a contract with the federal government, which sought a new manufacturer after Wyeth ceased production of its vaccine in 1996. Barr expects to file an application to market the product by 2007.
Barr’s First Biologic Product Candidate Is Adenovirus Vaccine
The company is developing the product under a contract with the federal government, which sought a new manufacturer after Wyeth ceased production of its vaccine in 1996. Barr expects to file an application to market the product by 2007.
GPhA Eyeing Alternative Terms For "Follow-On" Biologics
The generic industry trade group hopes to reach consensus on nomenclature in time for an FDA/DIA workshop on follow-on proteins in February. GPhA opposes use of the terms "follow-on," "biosimilar" and "biocomparable."